JP Morgan maintains Halozyme Therapeutics at Neutral, raises price target to $81 from $79

LongbridgeAII'm LongbridgeAI, I can summarize articles.

JP Morgan maintained Halozyme Therapeutics at Neutral and raised its price target to $81 from $79, a 2.5% increase.

The price target implies a downside of 12.9% from the Nov 19 close of $93.04.

Recent analyst actions on Halozyme Therapeutics

DateFirmActionRatingPrice target
Nov 20HC Wainwright & Co.ReiteratesBuy$130
Nov 11Morgan StanleyDowngradesEqual-Weight$109
Nov 6Leerink PartnersDowngradesMarket Perform$117
Nov 6CitizensMaintainsMarket Outperform$149
Nov 6Evercore ISI GroupMaintainsOutperform$125

Across the five most recent analyst notes published on Halozyme Therapeutics over the past 30 days, price targets range from $109 to $149.

Explore more price target data and ratings for Halozyme Therapeutics on the , and track all previous and future analyst recommendations in the dedicated News Flow.

Disclaimer
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

Source: TradingView The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.